1-4 of 4
Oliver Pelz-Ackermann
Close
Sort by
Journal Articles

BCR-ABL Kinase Domain Mutations and Their Kinetics on Second Line Dasatinib or Nilotinib Therapy in CML Patients after Imatinib Failure: A Cooperative Evaluation of Four Different Detection Methods.

Thomas Ernst, MD, Franz Gruber, MD, Oliver Pelz-Ackermann, PhD, Martin C. Mueller, MD, Ingvild Mikkola, PhD, Kimmo Porkka, MD, PhD, Dietger Niederwieser, MD, Andreas Hochhaus, MD, Thoralf Lange, MD
Journal: Blood
Blood (2007) 110 (11): 321.
https://doi.org/10.1182/blood.V110.11.321.321
Published: 2007
Journal Articles

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Oliver Pelz-Ackermann, Michael W.N. Deininger, PhD, Michael Cross, PhD, Kathrin Wildenberger, Rainer Krahl, PhD, Song-Yau Wang, MD, Haifa K. Al-Ali, MD, Dietger W. Niederwieser, MD, Thoralf Lange, MD
Journal: Blood
Blood (2007) 110 (11): 2918.
https://doi.org/10.1182/blood.V110.11.2918.2918
Published: 2007
Journal Articles

Fresh and Cryopreserved Umbilical Cord Blood Side Population Cells Have Comparable Immunophenotype and Function but Are Not Characterised by ABCG2 Expression.

Ruediger Alt, Dipl Biol, Oliver Pelz-Ackermann, Dipl. Biol., Dietmar Egger, M.D, Dietger W. Niederwieser, M.D., Michael Cross, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 4171.
https://doi.org/10.1182/blood.V108.11.4171.4171
Published: 2006
Journal Articles

First Results of a New PCR-Based Approach for a Sensitive and Quantitative Monitoring of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia.

Oliver Pelz-Ackermann, Michael W. Deininger, Michael Cross, Ines Kovacs, Christine Guenther, Knuth Krohn, Song-Yau Wang, Haifa K. Al-Ali, Dietger W. Niederwieser, Thoralf Lange
Journal: Blood
Blood (2006) 108 (11): 2191.
https://doi.org/10.1182/blood.V108.11.2191.2191
Published: 2006